期刊
EMERGING INFECTIOUS DISEASES
卷 23, 期 10, 页码 1746-1748出版社
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2310.170468
关键词
-
Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据